The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/bortezomib/rituxima...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Friedberg, Jonathan W., Vose, Julie M., Kelly, Jennifer L., Young, Faith, Bernstein, Steven H., Peterson, Derick, Rich, Lynn, Blumel, Susan, Proia, Nicole K., Liesveld, Jane, Fisher, Richard I., Armitage, James O., Grant, Steven, Leonard, John P.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2011
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3062293/
https://ncbi.nlm.nih.gov/pubmed/21239695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-11-314708
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg